Warning Letters Mount As FDA Completes Initial Inspections Of Under-The-Radar Facilities
Executive Summary
Later this year, FDA expects to complete initial inspections of every facility that manufactures drugs for the US market. As the agency visits under-the-radar facilities recently targeted as part of an effort to leave no site uninspected, it is finding that they are more likely to have serious drug GMP issues.
You may also be interested in...
Drug Quality Focus On Asia, OTCs Supported By US FDA's Second GMP Data Report
OTCs and other "no-application" products remain a drag on overall quality, agency finds in annual quality report, while India and China continue to pose challenges.
Drug Quality Focus On Asia, OTCs Supported By New US FDA Data
OTCs and other "no-application" products remain a drag on overall quality, agency finds in annual quality report, while India and China continue to pose challenges.
New Jersey OTC Firm Lacked GMP Basics, FDA Warning Letter Says
US FDA warns that Health Pharma USA was shipping product before its quality unit could review and test it.